Eric Blanchard

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.

Cooley advised the underwriters in Verona Pharma’s $150 million follow-on offering of 14,260,000 American depositary shares at a public offering price of $10.50 per American depositary share. Verona is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Lawyers Daniel Goldberg, Eric Blanchard, Div Gupta, Charlie Kim, Minkyu Park, Amiti Rothstein and Olivia Creser led the Cooley team.

Cooley advised the underwriters on The Clorox Company’s registered debt offering of $1.1 billion aggregate principal amount of investment grade unsecured senior notes. The offering consisted of $500 million of 4.400% senior notes due 2029 and $600 million of 4.600% senior notes due 2032. Partners Eric Blanchard and Richard Segal, and associates Evan Leitner, Matthew Kosior and Olivia Creser, led the Cooley team advising the underwriters.

Cooley advised Xometry on its offering of $287.5 million aggregate principal amount of 1% convertible senior notes due 2027. Partners Eric Blanchard, Mischi a Marca and Jason Savich led the Cooley team advising Xometry, which provides AI-enabled manufacturing equipment.

Cooley advised the joint sponsors and underwriters on ecommerce company Huitongda’s HK$2.2 billion (US$285 million) initial public offering of 51,606,200 H shares on the Hong Kong Stock Exchange, subject to the exercise of the underwriters’ option to purchase an additional 7,740,900 H shares. Partners Michael Yu and Will Cai led the Cooley team advising the joint sponsors and underwriters.